Nuclear unphosphorylated STAT3 correlates with a worse prognosis in human glioblastoma

Pathology Research and Practice

Volumn 212, Issue 6, 2016, Pages 517-523

  Rodrigues, Bruna R ^a   Queiroz Hazarbassanov, Nicolle ^a   Lopes, Marilene H ^b   Bleggi Torres, Luis F ^c   Suzuki, Sérgio ^a   Cunha, Isabela W ^a   Sanematsu, Paulo ^a   Martins, Vilma R ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Glioblastoma; Glioma; Immunohistochemistry; STAT3; u STAT3

Indexed keywords

STAT3 PROTEIN;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; ADULT; BRAIN TUMOR; CELL NUCLEUS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS;

ADULT; BRAIN NEOPLASMS; CELL NUCLEUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; PHOSPHORYLATION; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 84961267176     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2016.03.001     Document Type: Article

References (30)

1. [1] Alcantara Llaguno, S., Chen, J., Kwon, C.H., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15 (2009), 45–56.
2. [2] Louis, D.N., Ohgaki, H., Wiestler, O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2007), 97–109.
3. [3] Tibbetts, K.M., Emnett, R.J., Gao, F., et al. Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol. 117 (2009), 657–665.
4. [4] Ostrom, Q.T., Gittleman, H., Farah, P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro. Oncol. 15:Suppl. 2 (2013), 1–56.
5. [5] Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005), 987–996.
6. [6] Stupp, R., Hegi, M.E., Mason, W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORT C-NCIC trial. Lancet Oncol., 2009, 459–466.
7. [7] Gallego, O., Nonsurgical treatment of recurrent glioblastoma. Curr. Oncol. 22 (2015), 273–281.
8. [8] Xiong, A., Yang, Z., Shen, Y., et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers 6 (2014), 926–957.
9. [9] Bowman, T., Garcia, R., Turkson, J., Jove, R., STATs in oncogenesis. Oncogene 19 (2000), 2474–2488.
10. [10] Timofeeva, O.A., Chasovskikh, S., Lonskaya, I., et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J. Biol. Chem. 287 (2012), 14192–14200.
11. [11] Wen, Z., Zhong, Z., Darnell, J.E., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995), 241–250.
12. [12] Ouédraogo, Z.G., Müller-Barthélémy, M., Kemeny, J.L., et al. STAT3 serine 727 phosphorylation: a relevant target to radiosensitize human glioblastoma. Brain Pathol. 26 (2015), 18–30.
13. [13] Swiatek-Machado, K., Kaminska, B., STAT signaling in glioma cells. Glioma Signal 986 (2013), 189–208.
14. [14] See, A.P., Han, J.E., Phallen, J., et al. The role of STAT3 activation in modulating the immune microenvironment of GBM. J. Neurooncol. 110 (2012), 359–368.
15. [15] Yue, P., Turkson, J., Targeting STAT3 in cancer: how successful are we?. Expert Opin. Investig. Drugs 18 (2009), 45–56.
16. [16] Awad, A.J., Burns, T.C., Zhang, Y., et al. Targeting MET for glioma therapy. Neurosurg. Focus 37 (2014), 1–7.
17. [17] Kwak Y, Kim S, Park C, et al. C-MET overexpression and amplification in gliomas, 2015 8 14932–8.
18. [18] Shen, S., Niso-Santano, M.A.S., Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. PubMed Commons. Mol. Cell. 48 (2014), 667–680.
19. [19] Campos, A.H., Silva, A.A., Mota, L.D., et al. The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the AC camargo hospital. Biopreserv. Biobank. 10 (2012), 168–173.
20. [20] Lopes, M.H., Santos, T.G., Rodrigues, B.R., et al. Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival. Oncogene 34 (2015), 3305–3314.
21. [21] Kononen, J., Bubendorf, L., Kallioniemi, A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4 (1998), 844–847.
22. [22] Alvarenga, A.W., Coutinho-Camillo, C.M., Rodrigues, B.R., et al. A comparison between manual and automated evaluations of tissue microarray patterns of protein expression. J. Histochem. Cytochem. 61 (2013), 272–282.
23. [23] Verhaak, R.G.W., Hoadley, K.A., Purdom, E., et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell, 17, 2010, 98.
24. [24] Yang, J., Chatterjee-kishore, M., Staugaitis, S.M., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65 (2005), 939–947.
25. [25] Krex, D., Klink, B., Hartmann, C., et al. Long-term survival with glioblastoma multiforme. Brain 130 (2007), 2596–2606.
26. [26] Birner, P., Toumangelova-Uzeir, K., Natchev, S., et al. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J. Neurooncol. 100 (2010), 339–343.
27. [27] Lin, G.S., Yang, L.J., Wang, X.F., et al. STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med. Oncol., 31, 2014, 924.
28. [28] Soares, I.N., Caetano, F.A., Pinder, J., et al. Regulation of stress-inducible phosphoprotein 1 nuclear retention by protein inhibitor of activated STAT PIAS1. Mol. Cell. Proteomics 12 (2013), 3253–3270.
29. [29] Ungureanu, D., Vanhatupa, S., Kotaja, N., et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 102 (2003), 3311–3313.
30. [30] MD Anderson Cancer Center; National Institute of Health (2014). A Phase I Trial of WP1066. In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US); https:clinicaltrials.gov/ct2/show/NCT01904123 NLM Identifier: NCT01904123.